Our Pipeline

Our lead therapy, SON-001, is a patent-pending formulation of ibogaine co-administered with a cardiac-protective agent, that shows promise in treating challenging brain related conditions.

The iboga alkaloids and their uses are investigational and have not been approved by the U.S. Food and Drug Administration (FDA). This information is presented only for the purpose of providing a general overview and should not be construed as a recommendation for use, or FDA approval.

Our principal clinical program focuses on traumatic brain injury (TBI)-associated disabilities, a condition affecting millions of Americans every year1 with no effective treatment. Complications often include depression, anxiety, suicidality and PTSD. Subsequent indications may include a range of brain health disorders including neurodegenerative and neuropsychiatric conditions.

Soneira Research & Development Pipeline

  • Product

    Indication

    SON-001

    Traumatic Brain Injury (TBI) - associated disabilities

  • pre-clinical Pre-Clinical

    phase 1 Phase 1

    P2 Phase 2

    P3 Phase 3